SAVA
Cassava Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.32
+2.33%Jul 29, 2026, 12:00 UTC
Filana Therapeutics reported financial results for the second quarter ended June 30, 2026.
Source:Jun 15, 2026, 00:00 UTC
Filana Therapeutics, Inc. elected Richard J. Barry, Pierre Gravier, and Claude Nicaise as directors effective June 11, 2026.